consultant working with Eli Lilly, Compellis Pharmaceuticals and
Hypnion. He is a member of the Society for Neuroscience, CINP,
and has academic appointments in the Department of Psychiatry at
Indiana Universitys School of Medicine and in Pharmacology
at the Butler Universitys College of Pharmacy and Health
Sciences. Mr. Bymaster has a B.S. degree in Pharmacy from
Butler University and an M.S. degree in Pharmacology from
James C. Lancaster, Jr. has served as our Vice President
of Commercial Operations since August 2006. Previously,
Mr. Lancaster was most recently a marketing consultant from
March 2004 to August 2006 for Alkermes, Inc., G and S Research,
Corcept Therapeutics, Neuronetics and Eli Lilly, among others.
He continues in his role as a marketing consultant with
Neuronetics, Devonport and Pamlab. Mr. Lancaster has broad
commercial experience in the pharmaceutical industry, having
started off in June 1971 at the individual retail level as the
owner and store manager of his own pharmacy. From September 1977
to December 1999, he served as Sales Representative, Brand
Manager of Prozac and Global Marketing Director of Zyprexa, and
finally, from January 2000 to February 2003, the Director of
Commercial Affairs for Eli Lillys Global Neuroscience
division. In these roles, Mr. Lancaster was responsible for
working with advocacy, clinical, regulatory and sales groups.
Mr. Lancaster has a B.S. degree in Pharmacy from the
University of Tennessee.
Eckard Weber, M.D. is one of our co-founders and has
served as a member of our board of directors since our inception
in September 2002, and as the chairman of our board of directors
since March 2004. Dr. Weber is also a partner at Domain
Associates, L.L.C., a private venture capital management firm
focused on life sciences, a position he has held since 2001.
Dr. Weber has been a founder, founding chief executive
officer and board member of multiple biopharmaceutical companies
in the Domain portfolio including Cytovia, Inc., Acea
Pharmaceuticals, Inc., NovaCardia, Inc., Novalar
Pharmaceuticals, Inc., Novacea, Inc., Domain AntiBacterial
Acquisition Corporation, Ascenta Therapeutics, Inc., Konova,
Inc., Renovia, Inc., Tragara Pharmaceuticals, Syndax
Pharmaceuticals and Tobira Therapeutics, Inc. Dr. Weber is
currently a member of the board of directors of Novacea, Inc., a
publicly held biopharmaceutical company, and he currently serves
as interim Chief Executive Officer of Tramoxia Therapeutics,
Inc., an early-stage biopharmaceutical company. He is also a
current board member of Biovascular, Inc., Ocera, Inc., and
Diobex, Inc. Dr. Weber holds a B.S. from Kolping College in
Germany and an M.D. from the University of Ulm Medical School in
Louis C. Bock has served as a member of our board of
directors since April 2005. Mr. Bock is a Managing Director
of Scale Venture Partners, a venture capital firm. Mr. Bock
joined Scale Venture Partners in September 1997 from Gilead
Sciences, Inc., a biopharmaceutical company, where he held
positions in research, project management, business development
and sales from September 1989 to September 1997. Prior to
Gilead, he was a research associate at Genentech, Inc. from
November 1987 to September 1989. He currently serves as a
director of Ascenta Therapeutics, diaDexus Inc., SGX
Pharmaceuticals, Inc., Horizon Therapeutics and Zogenix, Inc.
and is responsible for Scale Venture Partners investments
in Prestwick Pharmaceuticals and Somaxon Pharmaceuticals.
Mr. Bock received his B.S. in Biology from California State
University, Chico and an M.B.A. from California State
University, San Francisco.
Brian H. Dovey has served as a member of our board of
directors since January 2004. Mr. Dovey is a managing
member of Domain Associates, L.L.C., a private venture capital
management firm focused on life sciences, and has served in this
capacity with the firm since 1988. He has served as chairman of
three companies and on the board of directors of approximately
30 additional companies, including Align Technology, Inc. and
Cardiac Science, Inc. Mr. Dovey currently serves on the
board of Neose Technologies, Inc., a publicly traded company.
Prior to joining Domain, Mr. Dovey spent six years at Rorer
Group, Inc. (now Aventis), including as president from 1986 to
1988. Previously, he was president of Survival Technology, Inc.,
medical products company. He also held management positions with
Howmedica, Inc., Howmet Corporation, and New York Telephone.
Mr. Dovey has served as both president and chairman of the
National Venture Capital Association. He is Chair of the Wistar
Institute, a non-profit preclinical biomedical research company.
Mr. Dovey is also Co-Dean of the Kauffman Fellows Program
at the Center for Venture Education.